Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Welireg (Belzutifan),WLRG2023-US-01,2023,USA,MDV,350,62,45,55,27.5,32,88,12,15,35,30,20,60,25,10,5,20,40,30,18,7,4,9,5,15,28,35,Cisplatin + Gemcitabine,Paclitaxel + Carboplatin,5-FU + Leucovorin,Capecitabine,0,0,0,15,40,55,10,45,45,65,2
Welireg (Belzutifan),WLRG2023-EU-02,2023,Germany,Claim Database,420,68,38,62,26.8,41,82,15,12,38,32,18,55,30,10,5,18,42,32,22,9,5,11,6,12,25,38,Cisplatin + Docetaxel,Carboplatin + Pemetrexed,5-FU + Oxaliplatin,Capecitabine,0,0,0,18,42,58,15,50,35,70,1.5
Welireg (Belzutifan),WLRG2024-JP-03,2024,Japan,MDV,280,70,52,48,24.5,25,90,10,20,40,25,15,65,20,10,5,25,45,25,15,6,3,8,4,10,22,30,S-1 + Cisplatin,Docetaxel + Carboplatin,UFT,Capecitabine,0,0,0,12,38,52,20,55,25,75,2.5
Welireg (Belzutifan),WLRG2024-CA-04,2024,Canada,Claim Database,380,65,48,52,28.0,35,85,13,18,36,28,18,58,27,10,5,22,38,28,20,8,4,10,5,14,26,33,Cisplatin + Gemcitabine,Paclitaxel + Carboplatin,5-FU + Leucovorin,Capecitabine,0,0,0,16,41,56,12,48,40,68,1.8
